

Congress of the United States
House of Representatives
Washington, DC 20515
June 10, 2026

The Honorable Jamieson Greer
Ambassador
United States Trade Representative
600 17th Street NW
Washington, D.C. 20508

The Honorable Howard Lutnick
Secretary
U.S. Department of Commerce
1401 Constitution Avenue NW
Washington, D.C. 20230

Dear Ambassador Greer and Secretary Lutnick,

We write to express our strong support for President Trump’s efforts to ensure that foreign nations pay their fair share for American pharmaceutical innovations. To build on the success of your recent landmark agreement with the United Kingdom, we urge you to use trade enforcement tools, including a Section 301 investigation, to dismantle foreign government policies that force American patients to pay a disproportionate share of global research and development costs for medicines.

For too long, wealthy foreign nations have reaped the benefits of American pharmaceutical innovation while using price controls and other unfair policies to avoid paying their fair share for these technologies. As a result, more than 70 percent of patented pharmaceutical profits in OECD countries come from U.S. sales even though the United States represents only one third of the OECD’s GDP.¹ Whereas past Presidents stood by and allowed foreign nations to take advantage of the United States, President Trump has rightly called for bold trade action to confront this problem.

We applaud the Administration for concluding the landmark U.S.-UK Arrangement on Pharmaceutical Pricing.² Thanks to President Trump’s leadership, this unprecedented agreement requires the UK to double its spending on innovative medicines, reducing the burden on the United States to finance these innovations for the world. This historic agreement shows that

¹ Council of Economic Advisers. (February 2020). *Funding the global benefits to biopharmaceutical innovation*. <https://trumpwhitehouse.archives.gov/wp-content/uploads/2020/02/Funding-the-Global-Benefits-to-Biopharmaceutical-Innovation.pdf>

² Office of the United States Trade Representative. (April 2, 2026). *Successful conclusion of the United States–United Kingdom arrangement on pharmaceutical pricing*. <https://ustr.gov/about/policy-offices/press-office/press-releases/2026/april/successful-conclusion-united-states-united-kingdom-arrangement-pharmaceutical-pricing>

Congress of the United States
House of Representatives
Washington, DC 20515

targeted trade negotiations on pharmaceutical pricing can deliver real benefits for American patients and taxpayers.

Unfortunately, other foreign governments are not taking President Trump's concerns on pharmaceutical pricing seriously. Nearly a year after President Trump's Executive Order called for an end to foreign freeloading,³ countries such as Germany, Japan, France and Canada have taken no steps to correct their market-distorting policies, many of which were documented by USTR in its recent National Trade Estimate and Special 301 Reports.⁴ Even worse, and despite the Administration's warnings, Germany and Switzerland recently announced plans to further suppress pharmaceutical spending and prices below market value, doubling down on their strategy to free-ride off the United States.⁵

We welcomed Ambassador Greer's February 20 announcement that USTR would initiate a Section 301 investigation on pharmaceutical pricing practices "on an accelerated timeframe."⁶ We believe this investigation is urgently needed to prevent further policy deterioration abroad, bring foreign governments to the negotiating table, and secure additional agreements modeled on the successful arrangement with the UK. We urge you to initiate this investigation as soon as possible to ensure that American patients are no longer forced to subsidize foreign healthcare systems and price controls.

Sincerely,

³ President Donald J. Trump. *Executive Order on Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients* (May 12, 2025) at Section 3, <https://www.whitehouse.gov/presidential-actions/2025/05/delivering-most-favored-nation-prescription-drug-pricing-to-american-patients/>

⁴ Office of the United States Trade Representative. (March 31, 2026). *USTR releases 2026 National Trade Estimate Report*. <https://ustr.gov/about/policy-offices/press-office/press-releases/2026/march/ustr-releases-2026-national-trade-estimate-report>

⁵ Whittle, H. (April 16, 2026). *German health minister announces billions in cutbacks*. Deutsche Welle. <https://www.dw.com/en/germany-health-care-spending-reform-cdu-spd/a-76796338>; Keystone-SDA. (February 19, 2026). *Switzerland mulls discounts on top-selling drugs to cut health costs*. Swissinfo.ch. <https://www.swissinfo.ch/eng/drug-pricing/top-selling-drugs-discounted-to-lower-premiums/90968142>

⁶ Office of the United States Trade Representative. (February 20, 2026). *Ambassador Greer issues statement on Supreme Court IEEPA decision*. <https://ustr.gov/about/policy-offices/press-office/press-releases/2026/february/ambassador-greer-issues-statement-supreme-court-ieepa-decision>

Congress of the United States

House of Representatives

Washington, DC 20515




Vern Buchanan
Member of Congress




Jodey C. Arrington
Member of Congress



Nicole Malliotakis
Member of Congress




Claudia Tenney
Member of Congress



Rudy Yakym III
Member of Congress



Earl L. "Buddy" Carter
Member of Congress



W. Gregory Steube
Member of Congress




Carol D. Miller
Member of Congress



Lloyd Smucker
Member of Congress



Darin LaHood
Member of Congress



Brian K. Fitzpatrick
Member of Congress



Pat Harrigan
Member of Congress




Mike Kelly
Member of Congress

Congress of the United States
House of Representatives
Washington, DC 20515



Derek Schmidt
Member of Congress




Jay Obernolte
Member of Congress



Thomas H. Kean, Jr.
Member of Congress



Gregory F. Murphy, M.D.
Member of Congress



Mike Kennedy, M.D.
Member of Congress



Ron Estes
Member of Congress



August Pfluger
Member of Congress



Aaron Bean
Member of Congress



Diana Harshbarger, Pharm.D.
Member of Congress



Gabe Evans
Member of Congress



Mariannette J. Miller-Meeks,
M.D.
Member of Congress



Kat Cammack
Member of Congress

Congress of the United States
House of Representatives
Washington, DC 20515



Rick W. Allen
Member of Congress



Addison P. McDowell
Member of Congress




Nathaniel Moran
Member of Congress



Tim Moore
Member of Congress




Richard Hudson
Member of Congress



Neal P. Dunn, M.D.
Member of Congress




Randy K. Weber, Sr.
Member of Congress



John Joyce, M.D.
Member of Congress



Brad Knott
Member of Congress



Vince Fong
Member of Congress



Beth Van Duyne
Member of Congress



Charles J. "Chuck"
Fleischmann
Member of Congress

Congress of the United States
House of Representatives
Washington, DC 20515




Cliff Bentz
Member of Congress



Julie Fedorchak
Member of Congress



Mike Carey
Member of Congress



John R. Moolenaar
Member of Congress



Craig A. Goldman
Member of Congress



Rich McCormick, MD, MBA
Member of Congress



Randy Feenstra
Member of Congress



Russ Fulcher
Member of Congress



H. Morgan Griffith
Member of Congress



Michael A. Rulli
Member of Congress



Erin Houchin
Member of Congress